China Meheco Corp. (600056.SH) is in talks on commercializing Pfizer’s new Covid-19 pill in China, but the discussions are still at an early stage, the state-owned pharmaceutical company said Monday.
Boosted by speculation that China Meheco might become Pfizer’s partner for marketing Paxlovid in China, the company’s Shanghai-traded shares surged by the daily limit of 10% during four consecutive sessions since last Wednesday.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.